Calls have been made for testosterone to be licensed in the UK for post-menopausal women.
Experts say the hormone is an important treatment for those experiencing reduced libido in midlife.
A taskforce brought together by the International Menopause Society (IMS) found testosterone could help women with hypoactive sexual desire dysfunction (HSDD) – characterised by a reduced interest in sex after menopause. HSDD affects about 32% of women in midlife, but testosterone for women is not licensed by the UK’s regulatory authorities.
The IMS statement on the hormone for women confirms post-menopausal women with HSDD can benefit from improved sexual desire, arousal, orgasm and pleasure, as well as reduced distress about sex.
Susan Davis, IMS President, said: “This statement reassures clinicians that a trial of testosterone therapy is appropriate for women with HSDD.”
Image credit | Shutterstock
